The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according toMaurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.
"Our view is that in the long term, this is not a two-horse race betweenEli Lilly Company(NYSE:LLY) andNovo Nordisk A/S(NYSE:NVO)," Maurits stated, challenging the prevailing notion of a duopoly in the weight-loss market.
Pot predicts that rising demand for weight loss treatments and expanded applications for GLP-1 drugs will drive this trillion-dollar market opportunity.
Login or create a forever free account to read this news
Sign up/Log in